GlassScriptPhysician profile
W Patrick Flanagan
NPI 1346240959
$2,285.74
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $370 · 2021: $754 · 2022: $409 · 2023: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $220.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $647.70 | 2019-2022 | |
| Teleflex LLC | $408.75 | 2021-2022 | |
| Neotract INC. | $296.71 | 2019-2020 | |
| Pfizer INC. | $169.60 | 2019-2020 | |
| Rochester Medical Corporation | $160.12 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $112.28 | 2023 | Quviviq |
| Urogen Pharma, INC. | $108.68 | 2023 | Jelmyto |
| Janssen Biotech, INC. | $57.46 | 2021 | |
| Endo Pharmaceuticals INC. | $53.83 | 2019-2022 | |
| Myovant Sciences INC. | $46.42 | 2021 | |
| Coloplast Corp | $43.38 | 2019 | |
| Medtronic USA, INC. | $39.53 | 2020 | |
| Allergan, INC. | $31.35 | 2021-2022 | |
| Urovant Sciences INC | $19.87 | 2021 | |
| Antares Pharma, INC. | $19.60 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $19.60 | 2019 | |
| Convatec INC. | $19.42 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.49 | 2022 | |
| Clarus Therapeutics INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw W Patrick Flanagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.